ATE295367T1 - Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält - Google Patents

Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält

Info

Publication number
ATE295367T1
ATE295367T1 AT95938023T AT95938023T ATE295367T1 AT E295367 T1 ATE295367 T1 AT E295367T1 AT 95938023 T AT95938023 T AT 95938023T AT 95938023 T AT95938023 T AT 95938023T AT E295367 T1 ATE295367 T1 AT E295367T1
Authority
AT
Austria
Prior art keywords
active ingredient
stranded oligonucleotide
double stranded
agent containing
containing same
Prior art date
Application number
AT95938023T
Other languages
English (en)
Inventor
Ken-Ichi Matsuo
Yoshikazu Sugimoto
Kenji Suzuki
Keisuke Ishida
Yuji Yamada
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE295367T1 publication Critical patent/ATE295367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT95938023T 1994-11-17 1995-11-16 Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält ATE295367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28306594 1994-11-17
PCT/JP1995/002348 WO1996016074A1 (en) 1994-11-17 1995-11-16 Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient

Publications (1)

Publication Number Publication Date
ATE295367T1 true ATE295367T1 (de) 2005-05-15

Family

ID=17660755

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95938023T ATE295367T1 (de) 1994-11-17 1995-11-16 Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält

Country Status (7)

Country Link
US (1) US6034234A (de)
EP (1) EP0733640B1 (de)
JP (1) JP3392143B2 (de)
AT (1) ATE295367T1 (de)
AU (1) AU3881095A (de)
DE (1) DE69534197T2 (de)
WO (1) WO1996016074A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035547A2 (en) * 2003-10-06 2005-04-21 Corgentech, Inc. E2f oligonucleotide decoy molecules
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
WO2006043722A1 (ja) * 2004-10-22 2006-04-27 Anges Mg, Inc. キメラ（ダブル）デコイ
CA2614295A1 (en) * 2005-06-06 2006-12-14 Anges Mg, Inc. Transcription factor decoy
JPWO2007072909A1 (ja) 2005-12-22 2009-06-04 アンジェスＭｇ株式会社 新規オリゴヌクレオチド及びそれから成るＮＦ−κＢデコイ
EP3199635B1 (de) 2007-05-11 2019-02-06 Adynxx, Inc. Genexpression und schmerzen
KR20100127300A (ko) * 2008-03-28 2010-12-03 안게스 엠지 인코포레이티드 전사 인자 디코이를 유효 성분으로 하는 외용제 조성물
CN104487096B (zh) 2012-05-10 2020-09-15 埃迪恩克斯股份有限公司 用于活性成分递送的配制物
AU2015301491A1 (en) 2014-08-15 2017-02-02 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
US20180223280A1 (en) * 2015-10-23 2018-08-09 Rena Therapeutics Inc. Nucleic acid complex

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012225A1 (en) * 1991-12-16 1993-06-24 Genentech, Inc. Novel tissue plasminogen activator variants
EP0580754A1 (de) * 1991-04-18 1994-02-02 The Salk Institute For Biological Studies Oligodeoxynukleotide und oligonukleotide, verwendbar als köder für proteine, die ausgewählt zu definierten dns-sequenzen binden
US5759803A (en) * 1992-05-13 1998-06-02 Dana-Farber Cancer Institute Recombinant retinoblastoma-associated protein 1 (E2F-1) polypeptides and cDNA
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5859226A (en) * 1993-07-29 1999-01-12 Regents Of The University Of California, The Polynucleotide decoys that inhibit MHC-II expression and uses thereof
US5473056A (en) * 1993-10-13 1995-12-05 Merck & Co., Inc. E2F-2, a novel mammalian transcription factor
EP0732929B1 (de) * 1993-10-29 2008-05-14 The Brigham And Women's Hospital, Inc. Therapeutische verwendung von cis-element-fallen in vivo
WO1995024223A1 (en) * 1994-03-08 1995-09-14 Thomas Jefferson University Inhibition of cell proliferation by e2f-1 antisense oligonucleotides
US5563036A (en) * 1994-04-29 1996-10-08 Tularik, Inc. Transcription factor-DNA binding assay
US5496831A (en) * 1994-05-13 1996-03-05 The General Hospital Corporation Inhibition of insulin-induced adiposis

Also Published As

Publication number Publication date
AU3881095A (en) 1996-06-17
DE69534197T2 (de) 2006-02-16
US6034234A (en) 2000-03-07
EP0733640A4 (de) 1999-11-24
DE69534197D1 (de) 2005-06-16
JP3392143B2 (ja) 2003-03-31
EP0733640A1 (de) 1996-09-25
EP0733640B1 (de) 2005-05-11
WO1996016074A1 (en) 1996-05-30

Similar Documents

Publication Publication Date Title
BE904421A (fr) Derives heterocycliques aromatiques et leur application dans les domaines therapeutique et cosmetique.
KR910009243A (ko) 치근막 질환 치료용 서방성 조성물
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
BR9811260A (pt) Pequenas moléculas úteis no tratamento de doença inflamatória
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
EE03681B1 (et) Asendatud imidasoolid, millel on vähivastane ja tsütokiine inhibeeriv toime
FI972086A7 (fi) Parannetun monilääkeresistenssiaktiivisuuden omaavat uudet aminohappoj ohdokset
ATE303993T1 (de) 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe
EP1562897A4 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DE69535805D1 (de) Neue Carbamate- und Harnstoffderivate als Mittel gegen Multidrugresistenz
EP0939621A4 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
MA27002A1 (fr) Amides d'acide anthranilique, procede pour les preparer, leur utilisation comme antiarythmiques et preparations pharmaceutiques les contenant
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE69525736D1 (de) Oligonukleotid und kanzerostatisches mittel das dieses als aktiven inhaltstoff enthält
BR9608789A (pt) Compostos de tetralina com atividade de mdr
PT902789E (pt) Derivados de androsteno
BG104899A (en) Antipicornaviral compounds and compositions, their pharmaceutical use and materials for their synthesis
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
DE69534197D1 (de) Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält
ATE82681T1 (de) 2',3'-dideoxy-3'-fluorothymidin und verwandte verbindungen zur behandlung von adenovirusinfektionen.
EP0932613A4 (de) Expressionsblockierung von virulenten faktoren in s. aureus
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
CA2216569A1 (fr) Utilisation de derives d'oxazolidinone comme agents anti-penetrants dans une composition cosmetique et/ou dermatologique

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties